Illumina’s corporate venturing unit took part in a round that brought the proteomic platform developer’s overall funding to $110m.
US-based proteomic research technology provider Alamar Biosciences closed an $80 series B round on Wednesday that included genomic biotechnology producer Illumina’s corporate venturing arm, Illumina Ventures.
Sherpa Healthcare Partners led the round, which was filled out by Morningside Ventures, Samsara Biocapital and Qiming Venture Partners. It puts the overall funding for the company at $110m.
Alamar is developing precision systems to accurately profile proteins from microlitre-level amounts of human plasma, using genomics to facilitate the early detection and prevention of…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
